Oncology Team C- Crossword

Edit Answers
123456789101112
Across
  1. 2. Choosing fulvestrant in 1st line over anastrozole will provide longer progression free survival .
  2. 4. The addition of everolimus to exemestance in the treatment of postmenopausal hormone receptor -positive advanced breast cancer.
  3. 6. Adjuvant Pertuzumab and Trastuzumab in Early HER-2 positive breast cancer.
  4. 8. Bevacizumab in first-line treatment of patients with unresectable,locally advanced,recurrent or metastatic NSCLC.
  5. 10. Adjuvant Doctaxel or Vinorelbine with or without Trastuzumab for Breast cancer.
  6. 12. Number of patients in BCIRG006
Down
  1. 1. In difficult to treat pupulation of advanced cervical cancer Bevacizumab improved OS and PFS.
  2. 3. Maintenance therapy with Bevacizumab with or without pemetrexed in NSCLC.
  3. 4. The addition of 1 year of adjuvant trastuzumab significantly improved DFS and overall survival among women with HER-2 positive Breast cancer.
  4. 5. Gemcitabine+Carboplatin+Bevacizumab until progression results in significant improvement in PFS compared to with Gemcitabine plus Carboplatin in platinum sensitive recurrent ovarian cancer.
  5. 7. %DFS at 4 year of follow up.
  6. 9. %OS with Canmab at 5 years follow up.
  7. 11. One year treatment with trastuzumab after adjuvant chemotherapy significantly improves DFS among women with HER 2 positive breast cancer.